PL3508483T3 - Związek dihydropirymidynowy oraz sposób jego wytwarzania i jego zastosowanie - Google Patents
Związek dihydropirymidynowy oraz sposób jego wytwarzania i jego zastosowanieInfo
- Publication number
- PL3508483T3 PL3508483T3 PL17870982T PL17870982T PL3508483T3 PL 3508483 T3 PL3508483 T3 PL 3508483T3 PL 17870982 T PL17870982 T PL 17870982T PL 17870982 T PL17870982 T PL 17870982T PL 3508483 T3 PL3508483 T3 PL 3508483T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- dihydropyrimidine compound
- dihydropyrimidine
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611015150 | 2016-11-18 | ||
| CN201710328659 | 2017-05-11 | ||
| EP17870982.0A EP3508483B1 (en) | 2016-11-18 | 2017-11-09 | Dihydropyrimidine compound and preparation method and use thereof |
| PCT/CN2017/110123 WO2018090862A1 (zh) | 2016-11-18 | 2017-11-09 | 二氢嘧啶类化合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3508483T3 true PL3508483T3 (pl) | 2022-02-07 |
Family
ID=62145967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17870982T PL3508483T3 (pl) | 2016-11-18 | 2017-11-09 | Związek dihydropirymidynowy oraz sposób jego wytwarzania i jego zastosowanie |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10696669B2 (pl) |
| EP (1) | EP3508483B1 (pl) |
| JP (1) | JP7139568B2 (pl) |
| KR (1) | KR102496508B1 (pl) |
| CN (1) | CN109790145B (pl) |
| AU (1) | AU2017359773B2 (pl) |
| BR (1) | BR112019005205A2 (pl) |
| CA (1) | CA3037218A1 (pl) |
| ES (1) | ES2901401T3 (pl) |
| IL (1) | IL266345A (pl) |
| MX (1) | MX2019005119A (pl) |
| MY (1) | MY194471A (pl) |
| PH (1) | PH12019550039A1 (pl) |
| PL (1) | PL3508483T3 (pl) |
| SG (1) | SG10202010180YA (pl) |
| WO (1) | WO2018090862A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108329308B (zh) | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | 一种二氢嘧啶类化合物的固体形式及其制备方法 |
| CA3140690A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators |
| CN112575389B (zh) * | 2019-09-30 | 2023-09-19 | 成都先导药物开发股份有限公司 | 一种dna编码化合物库的液相色谱纯化方法 |
| CN114853761A (zh) * | 2021-02-05 | 2022-08-05 | 刘沛 | 一种含有二氢嘧啶的双功能衍生物及其用途 |
| EP4289842A4 (en) | 2021-02-05 | 2025-01-08 | Hepagene Therapeutics (HK) Limited | Phenyldihydropyrimidine compound and use thereof |
| CN113512035B (zh) * | 2021-04-26 | 2023-11-24 | 山东大学 | 二氢嘧啶-泊马度胺缀合物及其制备方法与应用 |
| CN120157666A (zh) * | 2025-05-19 | 2025-06-17 | 中国医学科学院医药生物技术研究所 | 一种二氢嘧啶类化合物及其制备方法和应用、二氢嘧啶衍生物及其应用、药物组合物及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10013126A1 (de) * | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| WO2010069147A1 (zh) * | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101575318B (zh) * | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| MX2014011749A (es) | 2012-03-31 | 2015-01-22 | Hoffmann La Roche | 4-metil-dihidropirimidinas novedosas para el tratamiento y la prolifaxis de la infeccion por el virus de la hepatitis b. |
| US9953638B2 (en) | 2012-06-28 | 2018-04-24 | Nuance Communications, Inc. | Meta-data inputs to front end processing for automatic speech recognition |
| PL2888241T3 (pl) * | 2012-08-24 | 2017-12-29 | Sunshine Lake Pharma Co., Ltd. | 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby |
| CN103664925B (zh) * | 2012-09-07 | 2018-01-23 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| JP6113285B2 (ja) | 2012-09-10 | 2017-04-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療及び予防用の６−アミノ酸ヘテロアリールジヒドロピリミジン |
| CN103664899B (zh) * | 2012-09-11 | 2017-06-16 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| JP2016522271A (ja) * | 2013-03-20 | 2016-07-28 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | 細胞中のｈｂｖコアのための診断染色剤である蛍光ｈａｐ |
| WO2014161888A1 (en) | 2013-04-03 | 2014-10-09 | Janssen R&D Ireland | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| WO2014184328A1 (en) | 2013-05-17 | 2014-11-20 | F. Hoffmann-La Roche Ag | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| JP6524081B2 (ja) * | 2013-11-19 | 2019-06-05 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | ジヒドロピリミジン化合物及び医薬におけるその適用 |
| CN104650069B (zh) * | 2013-11-19 | 2019-04-19 | 广东东阳光药业有限公司 | 4-甲基二氢嘧啶类化合物及其在药物中的应用 |
| CN104650070B (zh) * | 2013-11-25 | 2018-09-14 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| ES2688600T3 (es) | 2013-11-27 | 2018-11-05 | Sunshine Lake Pharma Co., Ltd. | Procesos para preparar derivados de dihidropirimidina e intermedios de los mismos |
| AU2015226206B2 (en) | 2014-03-07 | 2017-03-16 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection |
| MY196243A (en) | 2014-03-28 | 2023-03-24 | Sunshine Lake Pharma Co Ltd | Dihydropyrimidine Compounds and Their Application In Pharmaceuticals |
| CN108329308B (zh) * | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | 一种二氢嘧啶类化合物的固体形式及其制备方法 |
-
2017
- 2017-11-09 PL PL17870982T patent/PL3508483T3/pl unknown
- 2017-11-09 BR BR112019005205A patent/BR112019005205A2/pt not_active Application Discontinuation
- 2017-11-09 SG SG10202010180YA patent/SG10202010180YA/en unknown
- 2017-11-09 CA CA3037218A patent/CA3037218A1/en active Pending
- 2017-11-09 ES ES17870982T patent/ES2901401T3/es active Active
- 2017-11-09 EP EP17870982.0A patent/EP3508483B1/en active Active
- 2017-11-09 CN CN201780057446.XA patent/CN109790145B/zh active Active
- 2017-11-09 AU AU2017359773A patent/AU2017359773B2/en active Active
- 2017-11-09 US US16/334,237 patent/US10696669B2/en active Active
- 2017-11-09 JP JP2019513814A patent/JP7139568B2/ja active Active
- 2017-11-09 MY MYPI2019001442A patent/MY194471A/en unknown
- 2017-11-09 KR KR1020197007824A patent/KR102496508B1/ko active Active
- 2017-11-09 MX MX2019005119A patent/MX2019005119A/es unknown
- 2017-11-09 WO PCT/CN2017/110123 patent/WO2018090862A1/zh not_active Ceased
-
2019
- 2019-03-18 PH PH12019550039A patent/PH12019550039A1/en unknown
- 2019-04-30 IL IL266345A patent/IL266345A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190225603A1 (en) | 2019-07-25 |
| JP2019535644A (ja) | 2019-12-12 |
| JP7139568B2 (ja) | 2022-09-21 |
| CN109790145B (zh) | 2020-09-22 |
| EP3508483B1 (en) | 2021-10-06 |
| EP3508483A1 (en) | 2019-07-10 |
| MY194471A (en) | 2022-11-30 |
| CN109790145A (zh) | 2019-05-21 |
| CA3037218A1 (en) | 2018-05-24 |
| KR102496508B1 (ko) | 2023-02-03 |
| MX2019005119A (es) | 2019-06-20 |
| BR112019005205A2 (pt) | 2019-06-11 |
| AU2017359773B2 (en) | 2021-05-20 |
| EP3508483A4 (en) | 2020-04-15 |
| WO2018090862A1 (zh) | 2018-05-24 |
| SG10202010180YA (en) | 2020-11-27 |
| KR20190077312A (ko) | 2019-07-03 |
| ES2901401T3 (es) | 2022-03-22 |
| IL266345A (en) | 2019-06-30 |
| US10696669B2 (en) | 2020-06-30 |
| AU2017359773A1 (en) | 2019-04-11 |
| PH12019550039A1 (en) | 2019-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201805805B (en) | Formulations and methods | |
| GB2546350B (en) | Compositions and methods | |
| EP3299369A4 (en) | Pyrido-azaheterecydic compound and preparation method and use thereof | |
| IL247713A0 (en) | Indazole 3-carboxyamides converted at the 5-position, their preparation and their use | |
| GB201514756D0 (en) | Compound and method of use | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| PT3357922T (pt) | Composto de pirimidina ou piridopiridona e sua aplicação | |
| ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
| GB201718876D0 (en) | Antithrombin-heparin compositions and methods | |
| IL266345A (en) | Dihydropyrimidine compound and method of preparation and use thereof | |
| GB201519128D0 (en) | Solid forms and methods of preparing the same | |
| GB201608779D0 (en) | Methods and compounds | |
| PL3398598T3 (pl) | Pochodne sulfonoamidowe oraz sposoby ich wytwarzania i zastosowanie | |
| ZA201704743B (en) | Mangiferin-6-o-berberine salt and preparation method and use thereof | |
| GB201608776D0 (en) | Methods and compounds | |
| IL257167A (en) | Antitussive compositions and methods | |
| GB201715820D0 (en) | Compositions and methods | |
| IL253174B (en) | Nano-particles and methods for their preparation | |
| GB201705626D0 (en) | Compositions and methods | |
| ZA201807665B (en) | Methods and compositions | |
| GB201512996D0 (en) | Compositions and methods | |
| GB2551275B (en) | Set-delayed cement compositions comprising pumice and associated methods | |
| GB2551279B (en) | Set-delayed cement compositions comprising pumice and associated methods | |
| EP3293179A4 (en) | Amide compound and the preparation method and use thereof | |
| GB201514413D0 (en) | Compositions and methods |